Institut Desbrest d'Epidémiologie et de Santé Publique, IDESP UMR UA11 INSERM, University of Montpellier.
WHO Collaborating Center for Classification Scientific Support, University Hospital of Montpellier, Montpellier, France.
Curr Opin Allergy Clin Immunol. 2021 Oct 1;21(5):411-417. doi: 10.1097/ACI.0000000000000778.
Anaphylactic reactions reported after Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) RNA vaccines were expected to be more frequent in atopic subjects and attributed to its polyethylene glycol component.
Anaphylaxis to SARS-CoV2 RNA vaccines is no more frequent than in any vaccine and direct proofs for the role of its polyethylene glycol component are lacking.
Vaccines against coronavirus disease 2019 (COVID-19) are an essential global intervention to control the current pandemic situation. Anaphylactic reactions have rapidly been reported after SARS-CoV2 RNA vaccines. This risk is now measured at 2.5-11/1 000 000 in the context of vaccine safety surveillance programs and only one case was documented to be due to polyethylene glycol. Suggestions for its role are indirect. The COVID-19 vaccination is rolling out vastly and surveillance programs are key to monitor severe adverse reactions, such as anaphylaxis. Anaphylaxis due to vaccine is extremely rare and specific cases should receive individualized investigation and care, highlighting the key role of allergists in the vaccination programmes.
预计在过敏体质人群中，严重急性呼吸综合征冠状病毒 2（SARS-CoV2）RNA 疫苗接种后发生过敏反应的频率更高，其原因与聚乙二醇（PEG）成分有关。
SARS-CoV2 RNA 疫苗接种后的过敏反应并不比其他疫苗更常见，缺乏其 PEG 成分作用的确切证据。
针对 2019 年冠状病毒病（COVID-19）的疫苗是控制当前大流行情况的重要全球干预措施。SARS-CoV2 RNA 疫苗接种后迅速报告了过敏反应。在疫苗安全监测计划中，这种风险的估计为每 100 万接种者中有 2.5-11 例，只有 1 例被记录为与 PEG 有关。关于其作用的建议是间接的。COVID-19 疫苗接种正在大规模开展，监测计划是监测严重不良反应（如过敏反应）的关键。疫苗接种引起的过敏反应极为罕见，应针对具体病例进行个体化调查和护理，突出了过敏专家在疫苗接种计划中的关键作用。
